anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention comprises compounds of the general formula: <FORM:0851780/IV(b)/1> where R represents an alkyl group having 1 to 5 carbon atoms, in the form of diastereoisomers or mixtures of diastereoisomers, and acidaddition salts thereof; the preparation thereof by etherifying the corresponding free hydroxy compound with an alcohol ROH, the reaction being carried out if desired at about 50 DEG C. to yield one diastereoisomer or below 5 DEG C. to yield the other, or by hydrogenating a compound of the formula: <FORM:0851780/IV(b)/2> where B represents a <FORM:0851780/IV(b)/3> , <FORM:0851780/IV(b)/4> , or <FORM:0851780/IV(b)/5> group in aqueous alcoholic medium where the alcohol is ROH, and, if desired converting the products of any of the above processes into their acid-addition salts; and pharmaceutical compositions containing the products. Lower melting point diastereoisomers may be converted into their higher melting point forms by treatment with a solution of hydrogen chloride in an alcohol ROH at between 20 DEG . and 50 DEG C., the alcohol being one in which the alkyl group R is the same as the alkyl group R of the ether being treated.  The products are diuretics. 3-Indolyl 2-piperidyl methanol and 3-(2-piper-idylmethyl)-indole are obtained as by-products in the catalytic hydrogenation of 3-picolylindole. 3-Indolyl 2-pyridyl methoxymethane is prepared by the action of methanolic hydrogen chloride on 3-indolyl 2-pyridyl methanol.ALSO:Pharmaceutical compositions comprise compounds of the general formula:  <FORM:0851780/VI/1> where R represents an alkyl group having 1 to 5 carbon atoms, in the form of diastereoisomers or mixtures thereof; or acid addition salts thereof; with suitable pharmaceutical diluents.  Oral preparations may be in the form of emulsions, solutions, suspensions, syrups, elixirs, capsules, tablets, pills, dispersible powders and granules.  The products are diuretics.
The intervention will be delivered as an internet-based stress recovery program for healthcare workers, comprising of six modules: introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These modules have been chosen after considering themes that could be most useful for healthcare workers under high stress. Each module consists of a psychoeducational and an exercise component. An intervention plan will be drawn up with the therapist prior to the start of the program, setting the intensity of engagement and the frequency of reminders. During the program, a therapist provides individual feedback on the completed exercises and can also be available on request.

The effect of the intervention will be compared with a control group that will use the program without an intervention plan. The intervention will be delivered in Lithuanian.
A compound of formula (I) or a salt thereof, wherein: R1 is hydrogen or C¿1-6?alkyl; R?2, R3 and R4¿ groups are independently hydrogen, halogen or C¿1-6?alkyl optionally substituted by one or more fluorine atoms. R?5 and R6¿ groups are independently hydrogen or C¿1-6?alkyl; X and Y are independently CH or nitrogen, provided that X is nitrogen when Y is nitrogen and both R?5 and R6¿ are hydrogen. The compounds exhibit enhanced 5HT¿2C? receptor antagonist activity profile. 5HT2C receptor antagonists are believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimer's disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of glaucoma, certain GI (gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome) as well as microvascular diseases such as macular oedema and retinopathy.
The second cohort (Cohort D) is planned to enroll in two groups of five subjects each, using 4:1 randomization (active:control). All subjects will be administered 0.5 mL DENV-1-LVHC (6.5 x 103 PFU/mL) on Day 1. After the inoculation, subjects will be evaluated in the clinic daily through day 18 (eighteen consecutive daily clinic visits). Dosing with placebo will commence on the morning of Day 8 and continue with a total of 28 doses taken twice daily through Day 21.
To test for drug compatibility with common intravenous solutions or medications, 20 mL of caffeine citrate injection were combined with 20 mL of a solution or medication. The physical appearance of the combined solutions was evaluated for precipitation. The admixtures were mixed for 10 minutes and then assayed for caffeine. The admixtures were then continually mixed for 24 hours, with further sampling for caffeine assays at 2, 4, 8, and 24 hours. 

Based on this testing, caffeine citrate injection, 60 mg per 3 mL is chemically stable for 24 hours at room temperature when combined with the following test products. 

  * Dextrose Injection, USP 5% 
  * 50% Dextrose Injection USP
FIELD: organic synthesis. SUBSTANCE: invention relates to therapeutic conjugates containing a therapeutic compound conjugated with one, two, or three fatty acyl groups. Therapeutic compounds are preferably nonsteroid anti-inflammatory agents including carboxylic group. Acyl groups are bound to therapeutic compounds through tromethamine and ethanolamine derivatives. New conjugates with formula I (presented in description) are described where x is nonsteroid anti-inflammatory compound containing carboxyl group; y is absent or represents one or two amino acids or a peptide; B is hydrogen or fatty acid acyloxymethyl group; and R 1 , R 2  and R 3 , the same or different, are hydrogen, methyl, ethyl, hydroxyl, or fatty acid acyl provided that at least one of R 1 , R 2  and R 3  is fatty acid acyl group. EFFECT: extended choice of therapeutic agents. 36 cl, 5 dwg, 1 tbl
Provided are surface-treated zinc oxide particles stably displaying high ultraviolet ray-shielding properties. Also provided are a dispersion liquid and a cosmetic that include said surface-treated zinc oxide particles. In addition, zinc oxide particles are provided whereby said surface-treated zinc oxide particles can be suitably produced. In the surface-treated zinc oxide particles, the particle surface of the zinc oxide particles has been treated using a silane coupling agent having an alkoxy group. The zinc oxide particles fulfil formula (1).　S·M/σ 2  ≥ 0.05 … (1) (S indicates the surface area of the zinc oxide particles (unit: m 2 /g), M indicates the Na content in the zinc oxide particles (unit: mg/kg), and σ indicates slurry conductivity (unit: μS/cm) when 10 parts by mass of zinc oxide particles and 90 parts by mass of pure water are mixed for an hour.)
The "Unified Protocol for Transdiagnostic Treatment of Emotional Disorders" (UP) is one of the most widely studied transdiagnostic manuals. Here, the investigators apply a group manual that has been modified from the published UP for individual therapy based on recommendations on group delivery from the UP Institute (personal communications) and integrations modifications necessary for the delivery in the Mental Health Service. Group UP-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions.
The mechanism underlying thrombus formation in acute coronary syndrome (ACS) involves both platelets and thrombin. While both pathways are targeted in acute care, platelet inhibition has been predominantly administered in the chronic phase, yet thrombin plays a key role in platelet activation and fibrin formation. Among ACS patients, there is also a persistent chronic increase in thrombin generation, which is associated with a higher rate of adverse events. In the setting of post-ACS care with rivaroxaban or vorapaxar, targeting thrombin has been associated with decreased thrombin generation and reduced cardiovascular events, but has been associated with increased bleeding risk. We explored the evidence supporting thrombin generation in the pathophysiology of recurrent events post-ACS and the role of thrombin as a viable therapeutic target. One specific target is factor XI inhibition, which is involved in thrombin generation, but may also allow for the preservation of normal hemostasis.
BACKGROUND: Although the long-term consequences of the Coronavirus Disease-2019 (COVID-19) pandemic are yet to be fully comprehended, a syndrome symptomatically akin to the COVID-19 disease has been defined, for children and adolescents, in February 2023 by the World Health Organization (WHO) as 'post COVID-19 condition' (PCC). Potential consequences of COVID-19 that affect developmental milestones in children and adolescents should be comprehended in their magnitude and duration. The aim is to investigate the most common symptoms and predictors or risk factors for pediatric PCC.
METHODS: In this umbrella review, the population of interest was defined as children and adolescents from 0 to 19 years old presenting PCC symptoms as defined by the WHO in the International Classification of Diseases. The intervention considered was general follow-up activity to monitor the patients' recovery status. No comparator was chosen, and the outcomes were symptoms of PCC and predictors or risk factors of developing PCC. Methodological quality, risk of bias and the level of overlap between studies were assessed. A random-effects meta-analytic synthesis of respective estimates with inverse variance study weighting was carried out, for the primary studies included by the reviews retrieved, regarding predictors or risk factors reported.
RESULTS: We identified six eligible systematic reviews, five with meta-analyses, from three databases. The most common symptoms reported were fatigue and respiratory difficulties; female sex and older age were the most reported factors associated with the development of pediatric PCC.
CONCLUSIONS: A deeper understanding of pediatric PCC requires well-designed and clearly defined prospective studies, symptom differentiation, and adequate follow-up.
Certain embodiments of the present invention provide a medical workflow system including a subvocal input device, an impulse processing component, and an information management system. The subvocal input device is capable of sensing nerve impulses in a user. The impulse processing component is in communication with the subvocal input device. The impulse processing component is capable of interpreting nerve impulses as dictation data and/or a command. The information management system is in communication with the impulse processing component. The information management system is capable of processing dictation data and/or a command from the impulse processing component.
Recommendations regarding contraceptive counseling and reproductive health differ amongst transgender and gender diverse (TGD) youth compared to cis-gender youth. TGD youth face unique health disparities including increased risk of sexually transmitted infections, sexual abuse and violence, and unwanted pregnancies. TGD youth also face inequities within the healthcare system including lack of access to providers and delay or avoidance of care. Both patients and providers also have misconceptions around pregnancy risk in transgender individuals assigned female at birth (AFAB) who are sexually active with people assigned male at birth. Limited existing literature demonstrates the need for contraceptive counseling that moves beyond cis- and heteronormative assumptions that start with pregnancy prevention and address concerns at the intersection of gender identity.

The Investigator's qualitative study will focus on creating best practices regarding equitable contraceptive counseling for TGD youth. The Investigator will recruit transgender youth who are AFAB, and currently or interested in using depo medroxyprogesterone (DMPA). Through focus groups and semi-structured interviews, the investigator hopes to gain the perspectives of and experiences of TGD youth with self-and clinic- administered DMPA. The investigator hopes the results of this study can guide providers in creating best practices and more equitable contraceptive counseling and measure to satisfaction of DMPA for TGD youth.
Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
Cardiovascular disease (CVD) imposes significant mortality and morbidity worldwide. Large population-based studies in Western cohorts have formed the foundations of our knowledge on the traditional risk factors of cardiovascular disease. Despite this, large gaps in our knowledge of CVD still exist. The clinical conundrum of the extremes of spectrums of CVD continues to baffle clinicians and researchers alike. These include patients without any major cardiovascular (CV) risk factors developing acute myocardial infarction (AMI) at a relatively young age (\<50-60 years old). At the other end of the spectrum, there are patients with a "full-house" CV risk factors with minor or no coronary artery disease. These suggest the presence of other factors that predispose these patients to AMI.Recent advancements in technology have led to exciting developments in our understanding of the development and prevention of CVD and AMI. The use of "big data" and "deep learning", advancements in genomics, metabolomics, and proteomics have the possibility of transforming this field. Modern prospective population-based studies aim to reclassify CV risk using integrated clinical and molecular biosignatures. However, these studies are based primarily in Western populations. Ethnic differences in CVD exist and currently in Asia, there is a dearth of such advanced data. In addition, in the Singapore Myocardial Infarction Registry (SMIR), it was reported about 1 in 4 of the AMI patients were aged 60 years or less from 2016 to 2020. The average number of AMI cases were about 900 and 2000 in patients aged \< 50 years and aged between 50-59 years respectively. In term of ethnic distribution of the AMI population, about 50% of young AMI patients were Chinese, followed by Malays and Indian. In this study, the investigators specifically aim to identify novel gene variants and novel protein/metabolite candidates associated with the onset of MI in relatively young Chinese,Malay and Indian patients with minimal standard CV risk factors such as diabetes, obesity, hypertension and hypercholesterolaemia. Through these omics-based analyses, these may therefore seek to help answer some of these questions and better improve our understanding of the development of CVD and MI, potentially developing novel preventive measures to reduce the risk or delay the onset and tailoring management plans to improve treatment outcomes and reduce adverse events for the young patients.
The role of hydrogen sulfide (H2S) on the phenotypic change of astrocytes following cerebral ischemia/reperfusion (I/R) in mice was investigated in present study. We tested the expression of glial fibrillary acidic protein (GFAP), A2 phenotype marker S100a10, and A1 phenotype marker C3 protein and assessed the change of BrdU/GFAP-positive cells, GFAP/C3-positive cells, and GFAP/S100a10-positive cells in mice hippocampal tissues to evaluate the change of astrocyte phenotypes following cerebral I/R. The role of H2S on the phenotypic change of astrocytes following cerebral I/R in mice was investigated by using H2S synthase cystathionine-γ-lyase (CSE) knockout mice (KO). The results revealed that cerebral I/R injury promoted the astrocytes proliferation of both A1 and A2 phenotypes, which were more significant in mice of H2S synthase CSE KO than in mice of wild type (WT). Interestingly, supplement with H2S could inhibit the A1 phenotype proliferation but promote the proliferation of A2 phenotype, suggesting that H2S could regulate the transformation of astrocytes to A2 phenotype following cerebral I/R, which is beneficial for neuronal recovery. Besides, we found that H2S-mediated change of astrocyte phenotype is related to inhibiting the RhoA/ROCK pathway. Furthermore, both H2S and ROCK inhibitor could ameliorate the brain injury of mice at 9 days after cerebral I/R. In conclusion, H2S regulates the phenotypic transformation of astrocytes to A2 phenotype following the cerebral I/R via inhibiting RhoA/ROCK pathway and then exerts the neuroprotective effect against the subacute brain injury.
BACKGROUND: The association between dietary protein intake and constipation remains inconclusive. The aim of this study was to investigate whether dietary protein intake is associated with constipation.
METHODS: This cross-sectional study included 13,941 adults from the 2005 to 2010 National Health and Nutrition Examination Survey. A weighted logistic regression analysis was used to control for confounding factors. In addition, weighted interaction and stratified analyses were conducted to ascertain the potential modifying factors.
RESULTS: The prevalence of constipation was 7.5% when constipation was defined by stool consistency and 3.5% when constipation was defined by stool frequency. After adjusting for covariates, an increase in dietary protein intake of 10 g was not associated with constipation, as defined by stool frequency (OR = 0.94, 95% CI = 0.54, 1.62) or stool consistency (OR = 1.02, 95% CI = 0.75, 1.39). Subgroup analyses revealed that dietary protein intake was associated with an increase in constipation defined by stool consistency risk in participants who consumed a low amount of carbohydrates (OR = 1.08, 95% CI = 1.02-1.14 for every 10-g increase in protein intake), but a decrease in risk in participants in the moderate-carbohydrate group (OR = 0.94, 95% CI = 0.89-0.99 for every 10-g increase in protein intake), suggesting a significant interaction (p = 0.001).
CONCLUSION & INFERENCES: Dietary protein intake is not associated with stool consistency or frequency-defined constipation. However, the association between dietary protein intake and constipation defined by stool consistency in participants with a low carbohydrate intake differed from that in participants with a moderate carbohydrate intake.
PURPOSE:A carcinostatic agent having low toxicity, comprising a polysilsesquioxane as an active ingredient. CONSTITUTION:A carcinostatic agent having extremely powerful carcinostatic effect and low toxicity to warm-blooded animals, containing 0.05-90wt% polysilsesquioxane consisting of a constitutional unit shown by the formulaIas an active ingredient. It can be applied to patients by oral, parenteral, or local medication. Its dose is 800-1mg/kg/day, preferably 500-10mg/kg/day, once a day or divided 3-5 times. The compound consisting of the constitutional unit shown by the formulaIis obtained as an amorphous white solid by hydrolyzing a compound shown by the formula II or formula III (R is 1-4C alkyl; X is Cl, Br, etc.).
Stress, such as from physical, metabolic or psychological trauma, is associated with enduring secondary complications leading to morbidity and/or death in subjects that receive the stress insult. The epigenetic oxidative stress response to a stress insult is characterized by (a) global epigenetic events such as changes in DNA methylation and phosphorylation of Ser10 and acetylation of Lys9/14 residues of histone-3 (b) significant systemic elevations in analytes of oxidative stress in body fluids such as blood or urine and (c) deterioration of clinically relevant parameters such as glycemic control, organ function, lean body mass and rate of healing. The applicant teaches a method of counteracting the grave systemic effects of stress insult with reference to the epigenetic oxidative stress response, by daily subcutaneous bolus injections of nephrilin peptide beginning soon after insult and continuing for seven days. These methods of combating epigenetic oxidative stress response are new and have not been described in the prior art. Specifically, the use of nephrilin (acting on its target, Rictor complex) to obviate the epigenetic changes in trauma that result in systemic oxidative stress, is new. Previously disclosed work on nephrilin had not described its effects on epigenetic change (mechanism) or oxidative stress (readout). The relevance of this particular epigenetic-oxidative-stress cascade to clinically relevant outcomes such as loss of organ function, glycemic control or lean body mass was unknown, as was the use of nephrilin molecule to counteract these phenomena. The invention relates to the use of specific therapeutic agents such as nephrilin to ameliorate the epigenetic oxidative stress response, and specifically the above-mentioned clinically relevant parameters.
Disclosed is a novel vaccine. Since a prion protein (PrP) is a major constituent molecule of prion, the tolerance of a host against an endogenous prion protein has hampered the development of prion vaccines. In fact, in mice immunized with a murine recombinant prion protein, only a very weak antibody reaction was observed and no prophylactic effect was not shown against the development of a disease induced by a murine prion. In contrast, recombinant heterogeneous prion proteins derived from hamster, sheep, bovine and human showed a very potent immunogenicity in mice. An anti-human or anti-bovine prion protein antibody respectively recognized an epitope on a human or bovine prion epitope corresponding to the epitope on an antibody (an antigenic determinant) which is known to exert a prophylactic effect on murine prion. This fact suggests that immunization with a heterogeneous protein is effective for the prevention of the infection with a prion derived from a species other than that of a host. Further, the immunized mice produced a considerable amount of anti-prion protein autoantibodies, and the mice immunized with bovine prion protein and sheep prion protein showed significantly delayed onset after the infection with murine prion by intraperitoneal administration compared to un-immunized mice. These results suggest that the immunization with a heterogeneous, not autologous, prion protein acts in a prophylactic manner on the infection with a prion derived from a species different from or same as that of the host, and that a molecule analogous to a prion protein has the potential for becoming a potent prion vaccine.
Participants in this group will follow Boston IVF's standard natural thaw cycle protocol. Participants will be coming for blood and transvaginal ultrasound monitoring around day 11 of the participants cycle. Once the participant has a final measurement of the endometrial lining ≥ 7 mm (T1), a 17mm ovarian follicle, and a progesterone \< 1.2 ng/mL, the doctor of record will schedule the patient to receive a trigger injection to induce ovulation followed by an embryo transfer 6-7 days later. Participants may be started on vaginal progesterone 4 days after the trigger injection for added supplementation per the doctor of record.
The invention belongs to the technical field of novel coronavirus infection disease prevention/treatment medicines, and particularly relates to an antibody or antigen binding fragment thereof for resisting novel coronavirus RBD protein and application thereof. The antibody can select an antibody a or an antibody b, the amino acid sequence of a light chain variable region of the antibody a is shown as SEQ ID NO. 7, and the amino acid sequence of a heavy chain variable region of the antibody a is shown as SEQ ID NO. 8; the amino acid sequence of the light chain variable region of the antibody b is shown as SEQ ID NO. 19, and the amino acid sequence of the heavy chain variable region of the antibody b is shown as SEQ ID NO. 20. The antibody has binding capacity of nM level for each subtype of BA.4/.5, XBB.1.5, XBB.1.16 and EG5.1 of novel coronavirus (Omikovia variant), has excellent neutralizing capacity for the variant strain, and can be applied to the preparation of medicines for preventing/treating the original strain of the novel coronavirus and diseases infected by the variant strain.